Sanofi Boasts a Dividend Yield of 5.4%, Trades Below 9x Earnings, and Just Got an FDA Win. Are Income Investors Missing a Rare Opportunity?
The company has increased its dividend for 30 consecutive years.
Sanofi, a French multinational pharmaceutical company, offers a compelling opportunity for income investors. The stock boasts a generous quarterly dividend of $0.61, yielding approximately 5.4% annually. This yield increases to near 11% when considering the company's stock buybacks. Furthermore, Sanofi has raised its dividend for an impressive 30 consecutive years, placing it among the European Dividend Aristocrats.
Despite these attractive features, Sanofi's share price has declined by around 6.5% this year. This decrease can be attributed, in part, to the company's decision to cancel several major late-stage programs, which has raised valid concerns among investors regarding the strength of its drug pipeline. However, these challenges may present a unique opportunity for income-seeking investors.
Written by urgent.news from Motley Fool's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
